The Role of Vitamin E in Breast Cancer Treatment and Prevention: Current Perspectives

Victor    A.   de Oliveira; Irislene    C.   Pereira; Thaís    R.   Nogueira; Jorddam    A.   Martins; Gilmara       Péres-Rodrigues; Betânia       de Jesus e Silva de Almendra; Vladimir    C.   Silva; Dalton    D.   Júnior; Francisco    L.T.   Leal; Joáo    M.   de Castro e Sousa; Felipe    C.C.   da Silva; Ana    A.   de Carvalho Melo Cavalcanti; Adriana       de Azevedo Paiva

doi:10.2174/1573401316999200614164711

Abstract

Background: Regarding the multifactorial etiology of breast cancer, food choices, as well as dietary intake, are the main modified factors in cancer prevention. In this sense, understanding molecular pathways involved in breast cancer proliferation can help determine the mechanisms of action of organic compounds such as antioxidant vitamins that are known to protect against cancer.

Objective: Assess the mechanism of action of vitamin E in breast cancer modulation, with emphasis on important markers of tumor development.

Methods: It is a systematic review carried out in PubMed and Web of Science databases, from the last 5 years, in Portuguese, English and Spanish. The following terms were selected according to The Medical Subject Headings (MeSH): “breast cancer” OR “breast neoplasms”, “tocopherol” OR “tocotrienols” OR “vitamin E”, as equated terms.

Results: A total of 595 articles were found and 25 were selected according to inclusion criteria. Vitamin E has been related to suppression/overexpression of important tumorigenic pathways, mainly associated with proliferation, energy metabolism, chemosensitivity and invasion/metastasis. Clinical studies of vitamin E supplementation are needed to assess the dose/response effect on breast cancer patients.

Conclusion: The safety of vitamin E supplementation is still controversial due to current studies design available. However, when vitamin E is supplemented, the dose and therapeutic regimen must be carefully decided, including the route of administration and breast cancer subtypes to enhance desired effects and minimize unwanted side effects.

Keywords: Breast neoplasms, chemotherapy, modulation, pathogenesis, tocopherol, tocotrienols.

« Previous Next »

Graphical Abstract

[1] 
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin  2015; 65(2): 87-108.
[2] 

                         INCA (Instituto Nacional do Câncer). Estimativa 2020: Incidência de Câncer no Brasil / Instituto Nacional de Câncer José Alencar Gomes da Silva. Rio de Janeiro: Coordenação de Prevenção e Vigilância
                     2019. Available from
                    https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-decancer-no-brasil.pdf
[3] 
Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and inflammation: new insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book  2013; 33(1): 46-51.
[http://dx.doi.org/10.14694/EdBook_AM.2013.33.46] [PMID:  23714453] 
[4] 
Chen SI, Hsieh CC. Why are women with obesity more likely to develop breast cancer. Future Oncol  2018; 14(16): 1523-6.
[http://dx.doi.org/10.2217/fon-2018-0125] 
[5] 
Nattenmüller CJ, Kriegsmann M, Sookthai D, et al. Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study. BMC Cancer  2018; 18(1): 616.
[http://dx.doi.org/10.1186/s12885-018-4548-6] [PMID:  29855282] 
[6] 
Bonner MY, Arbiser JL. The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer. Future Med Chem  2014; 6(12): 1413-22.
[http://dx.doi.org/10.4155/fmc.14.86] [PMID:  25329197] 
[7] 
Liu RZ, Garcia E, Glubrecht DD, et al. CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid. Mol Cancer  2015; 14(1): 129.
[http://dx.doi.org/10.1186/s12943-015-0380-7] [PMID:  26142905] 
[8] 
Hu X, Li S, Zhou L, et al. Effect of vitamin E supplementation on uterine cervical neoplasm: A meta-analysis of case-control studies. PLoS One  2017; 12(8)e0183395
[http://dx.doi.org/10.1371/journal.pone.0183395] [PMID:  28829815] 
[9] 
INCA (Instituto Nacional do Câncer) Ações de enfermagem para o controle do câncer: uma proposta de integração ensino-serviço  Rio de Janeiro 2008. Available from
                    https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//acoes-enfermagem-controlecancer.pdf.
[10] 
Suhail N, Bilal N, Khan HY, et al. Effect of vitamins C and E on antioxidant status of breast-cancer patients undergoing chemotherapy. J Clin Pharm Ther  2012; 37(1): 22-6.
[http://dx.doi.org/10.1111/j.1365-2710.2010.01237.x] [PMID:  21204889] 
[11] 
Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA  2007; 297(8): 842-57.
[http://dx.doi.org/10.1001/jama.297.8.842] [PMID:  17327526] 
[12] 
Papaioannou D, Cooper KL, Carroll C, et al. Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta-analysis. Colorectal Dis  2011; 13(10): 1085-99.
[http://dx.doi.org/10.1111/j.1463-1318.2010.02289.x] [PMID:  20412095] 
[13] 
Vollbracht C, Schneider B, Leendert V, et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo  2011; 25(6): 983-90.
[14] 
Ju J, Picinich SC, Yang Z, et al. Cancer-preventive activities of tocopherols and tocotrienols. Carcinogenesis  2010; 31(4): 533-42.
[http://dx.doi.org/10.1093/carcin/bgp205] [PMID:  19748925] 
[15] 
Cardenas E, Ghosh R. Vitamin E: a dark horse at the crossroad of cancer management. Biochem Pharmacol  2013; 86(7): 845-52.
[http://dx.doi.org/10.1016/j.bcp.2013.07.018] [PMID:  23919929] 
[16] 
Müller L, Theile K, Böhm V. In vitro antioxidant activity of tocopherols and tocotrienols and comparison of vitamin E concentration and lipophilic antioxidant capacity in human plasma. Mol Nutr Food Res  2010; 54(5): 731-42.
[http://dx.doi.org/10.1002/mnfr.200900399] [PMID:  20333724] 
[17] 
Kanchi MM, Shanmugam MK, Rane G, et al. Tocotrienols: the unsaturated sidekick shifting new paradigms in vitamin E therapeutics. Drug Discov Today  2017; 22(12): 1765-81.
[http://dx.doi.org/10.1016/j.drudis.2017.08.001] [PMID:  28789906] 
[18] 
Alawin OA, Ahmed RA, Ibrahim BA, et al. Antiproliferative effects of γ-tocotrienol are associated with lipid raft disruption in HER2-positive human breast cancer cells. J Nutr Biochem  2016; 27: 266-77.
[http://dx.doi.org/10.1016/j.jnutbio.2015.09.018] [PMID:  26507543] 
[19] 
Jiang Q. Natural forms of vitamin E as effective agents for cancer prevention and therapy. Adv Nutr  2017; 8(6): 850-67.
[http://dx.doi.org/10.3945/an.117.016329] [PMID:  29141970] 
[20] 
Wada S. Chemoprevention of tocotrienols: the mechanism of antiproliferative effects. Forum Nutr  2009; 204-16.
[http://dx.doi.org/10.1159/000212752] 
[21] 
Catalgol B, Batirel S, Ozer NK. Cellular protection and therapeutic potential of tocotrienols. Curr Pharm Des  2011; 17(21): 2215-20.
[http://dx.doi.org/10.2174/138161211796957436] [PMID:  21774780] 
[22] 
Ahsan H, Ahad A, Iqbal J, et al. Pharmacological potential of tocotrienols: a review. Nutr Metab  2014; 11(1): 52.
[http://dx.doi.org/10.1186/1743-7075-11-52] [PMID:  25435896] 
[23] 
De Silva L, Chuah LH, Meganathan P, et al. Tocotrienol and cancer metastasis. Biofactors  2016; 42(2): 149-62.
[http://dx.doi.org/10.1002/biof.1259] [PMID:  26948691] 
[24] 
Springett GM, Husain K, Neuger A, et al. A phase I safety, pharmacokinetic, and pharmacodynamic presurgical trial of vitamin E δ-tocotrienol in patients with pancreatic ductal neoplasia. EBioMedicine  2015; 2(12): 1987-95.
[http://dx.doi.org/10.1016/j.ebiom.2015.11.025] [PMID:  26844278] 
[25] 
Mahipal A, Klapman J, Vignesh S, et al. Pharmacokinetics and safety of vitamin E δ-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites. Cancer Chemother Pharmacol  2016; 78(1): 157-65.
[http://dx.doi.org/10.1007/s00280-016-3048-0] [PMID:  27278668] 
[26] 
Shen CL, Mo H, Yang S, et al. Safety and efficacy of tocotrienol supplementation for bone health in postmenopausal women: protocol for a dose-response double-blinded placebo-controlled randomised trial. BMJ Open  2016; 6(12)e012572
[http://dx.doi.org/10.1136/bmjopen-2016-012572] [PMID:  28011809] 
[27] 
Li G, Lee MJ, Liu AB, et al. The antioxidant and anti-inflammatory activities of tocopherols are independent of Nrf2 in mice. Free Radic Biol Med  2012; 52(7): 1151-8.
[http://dx.doi.org/10.1016/j.freeradbiomed.2011.12.005] [PMID:  22226829] 
[28] 
Chen JX, Liu A, Lee MJ, et al. δ- and γ-tocopherols inhibit phIP/DSS-induced colon carcinogenesis by protection against early cellular and DNA damages. Mol Carcinog  2017; 56(1): 172-83.
[http://dx.doi.org/10.1002/mc.22481] [PMID:  27175800] 
[29] 
Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA  2009; 301(1): 52-62.
[http://dx.doi.org/10.1001/jama.2008.862] [PMID:  19066368] 
[30] 
Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA  2009; 301(1): 39-51.
[http://dx.doi.org/10.1001/jama.2008.864] [PMID:  19066370] 
[31] 
Das Gupta S, Suh N. Tocopherols in cancer: An update. Mol Nutr Food Res  2016; 60(6): 1354-63.
[http://dx.doi.org/10.1002/mnfr.201500847] [PMID:  26751721] 
[32] 
Smolarek AK, So JY, Thomas PE, et al. Dietary tocopherols inhibit cell proliferation, regulate expression of ERα, PPARγ, and Nrf2, and decrease serum inflammatory markers during the development of mammary hyperplasia. Mol Carcinog  2013; 52(7): 514-25.
[http://dx.doi.org/10.1002/mc.21886] [PMID:  22389237] 
[33] 
Wells SR, Jennings MH, Rome C, et al. α-, γ- and δ-tocopherols reduce inflammatory angiogenesis in human microvascular endothelial cells. J Nutr Biochem  2010; 21(7): 589-97.
[http://dx.doi.org/10.1016/j.jnutbio.2009.03.006] [PMID:  19443199] 
[34] 
Bak MJ, Das Gupta S, Wahler J, et al. Inhibitory effects of γ-and δ-tocopherols on estrogen-stimulated breast cancer in vitro and in vivo. Cancer Prev Res   2017; 10(3): 188-97.
[http://dx.doi.org/10.1158/1940-6207.CAPR-16-0223] [PMID:  28096236] 
[35] 
Guan F, Li G, Liu AB, et al. δ- and γ-tocopherols, but not α-tocopherol, inhibit colon carcinogenesis in azoxymethane-treated F344 rats. Cancer Prev Res (Phila)  2012; 5(4): 644-54.
[http://dx.doi.org/10.1158/1940-6207.CAPR-11-0521] [PMID:  22366914] 
[36] 
Zhao Y, Lee MJ, Cheung C, et al. Analysis of multiple metabolites of tocopherols and tocotrienols in mice and humans. J Agric Food Chem  2010; 58(8): 4844-52.
[http://dx.doi.org/10.1021/jf904464u] [PMID:  20222730] 
[37] 
Das Gupta S, So JY, Wall B, et al. Tocopherols inhibit oxidative and nitrosative stress in estrogen-induced early mammary hyperplasia in ACI rats. Mol Carcinog  2015; 54(9): 916-25.
[http://dx.doi.org/10.1002/mc.22164] [PMID:  24782330] 
[38] 
David JA, Rifkin WJ, Rabbani PS, et al. The Nrf2/Keap1/ARE pathway and oxidative stress as a therapeutic target in type II diabetes mellitus. J Diabetes Res  2017; 20174826724
[http://dx.doi.org/10.1155/2017/4826724] [PMID:  28913364] 
[39] 
Jaffer T, Ma D. The emerging role of chemokine receptor CXCR2 in cancer progression. Transl Cancer Res  2016; 5(Suppl. 4): S616-28.
[http://dx.doi.org/10.21037/tcr.2016.10.06] 
[40] 
Sharma B, Nawandar DM, Nannuru KC, et al. Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis. Mol Cancer Ther  2013; 12(5): 799-808.
[http://dx.doi.org/10.1158/1535-7163.MCT-12-0529] [PMID:  23468530] 
[41] 
Yim CY, Bikorimana E, Khan E, et al. G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer. Cell Cycle  2017; 16(21): 2146-55.
[http://dx.doi.org/10.1080/15384101.2017.1371884] [PMID:  28910567] 
[42] 
Parajuli P, Tiwari RV, Sylvester PW. Anti-proliferative effects of γ-tocotrienol are associated with suppression of c-Myc expression in mammary tumour cells. Cell Prolif  2015; 48(4): 421-35.
[http://dx.doi.org/10.1111/cpr.12196] [PMID:  26096843] 
[43] 
Zhao L, Zhao X, Zhao K, et al. The α-tocopherol derivative ESeroS-GS induces cell death and inhibits cell motility of breast cancer cells through the regulation of energy metabolism. Eur J Pharmacol  2014; 745: 98-107.
[http://dx.doi.org/10.1016/j.ejphar.2014.09.050] [PMID:  25446928] 
[44] 
Larouche D, Hanna M, Chang SL, et al. Evaluation of antioxidant intakes in relation to inflammatory markers expression within the normal breast tissue of breast cancer patients. Integr Cancer Ther  2017; 16(4): 485-95.
[http://dx.doi.org/10.1177/1534735416676584] [PMID:  27903840] 
[45] 
Lee HJ, Ju J, Paul S, et al. Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-γ. Clin Cancer Res  2009; 15(12): 4242-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-3028] [PMID:  19509159] 
[46] 
Hamidullah  ChangkijaB, Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat  2012; 133(1): 11-21.
[http://dx.doi.org/10.1007/s10549-011-1855-x] [PMID:  22057973] 
[47] 
Abranches MV, Mendes MCS. Pena Gd, et al Antioxidant vitamins and cytokines are altered in breast cancer. Eur J Cancer Prev  2011; 20(5): 403-10.
[http://dx.doi.org/10.1097/CEJ.0b013e328347618e] [PMID:  21566526] 
[48] 
Hoellen F, Reibke R, Hornemann K, et al. Cancer in pregnancy. Part I: basic diagnostic and therapeutic principles and treatment of gynecological malignancies. Arch Gynecol Obstet  2012; 285(1): 195-205.
[http://dx.doi.org/10.1007/s00404-011-2058-8] [PMID:  21858441] 
[49] 
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell  2011; 144(5): 646-74.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID:  21376230] 
[50] 
Laezza C, D’Alessandro A, Paladino S, et al. Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells. Eur J Cancer  2012; 48(16): 3112-22.
[http://dx.doi.org/10.1016/j.ejca.2012.02.062] [PMID:  22425263] 
[51] 
Matsuda Y, Schlange T, Oakeley EJ, et al. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res  2009; 11(3): R32.
[http://dx.doi.org/10.1186/bcr2317] [PMID:  19473496] 
[52] 
Ahmed RA, Alawin OA, Sylvester PW. γ-Tocotrienol reversal of epithelial-to-mesenchymal transition in human breast cancer cells is associated with inhibition of canonical Wnt signalling. Cell Prolif  2016; 49(4): 460-70.
[http://dx.doi.org/10.1111/cpr.12270] [PMID:  27323693] 
[53] 
Algayadh IG, Dronamraju V, Sylvester PW. Role of Rac1/WAVE2 signaling in mediating the inhibitory effects of γ-tocotrienol on mammary cancer cell migration and invasion. Biol Pharm Bull  2016; 39(12): 1974-82.
[http://dx.doi.org/10.1248/bpb.b16-00461] [PMID:  27904039] 
[54] 
Hynes NE, Stoelzle T. Key signalling nodes in mammary gland development and cancer. Myc Breast Cancer Res  2009; 11(5): 210.
[http://dx.doi.org/10.1186/bcr2406] [PMID:  19849814] 
[55] 
Wang C, Ju H, Shen C, et al. miR-429 mediates δ-tocotrienol-induced apoptosis in triple-negative breast cancer cells by targeting XIAP. Int J Clin Exp Med  2015; 8(9): 15648-56.
[PMID:  26629059] 
[56] 
Diao QX, Zhang JZ, Zhao T, et al. Vitamin E promotes breast cancer cell proliferation by reducing ROS production and p53 expression. Eur Rev Med Pharmacol Sci  2016; 20(12): 2710-7.
[PMID:  27383327] 
[57] 
Sotgia F, Martinez-Outschoorn UE, Pavlides S, et al. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res  2011; 13(4): 213.
[http://dx.doi.org/10.1186/bcr2892] [PMID:  21867571] 
[58] 
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science  2009; 324(5930): 1029-33.
[http://dx.doi.org/10.1126/science.1160809] [PMID:  19460998] 
[59] 
Birsoy K, Possemato R, Lorbeer FK, et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature  2014; 508(7494): 108-12.
[http://dx.doi.org/10.1038/nature13110] [PMID:  24670634] 
[60] 
Zhao J, Zhang J, Yu M, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene  2013; 32(40): 4814-24.
[http://dx.doi.org/10.1038/onc.2012.494] [PMID:  23128392] 
[61] 
Dong JY, He K, Wang P, et al. Dietary fiber intake and risk of breast cancer: a meta-analysis of prospective cohort studies. Am J Clin Nutr  2011; 94(3): 900-5.
[http://dx.doi.org/10.3945/ajcn.111.015578] [PMID:  21775566] 
[62] 
Cheng G, Zielonka J, McAllister DM, et al. Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer  2013; 13(1): 285.
[http://dx.doi.org/10.1186/1471-2407-13-285] [PMID:  23764021] 
[63] 
Wong RS, Radhakrishnan AK. Tocotrienol research: past into present. Nutr Rev  2012; 70(9): 483-90.
[http://dx.doi.org/10.1111/j.1753-4887.2012.00512.x] [PMID:  22946849] 
[64] 
Pierpaoli E, Viola V, Pilolli F, et al. γ- and δ-tocotrienols exert a more potent anticancer effect than α-tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression. Life Sci  2010; 86(17-18): 668-75.
[http://dx.doi.org/10.1016/j.lfs.2010.02.018] [PMID:  20188744] 
[65] 
Viola V, Ciffolilli S, Legnaioli S, et al. Mitochondrial-dependent anticancer activity of δ-tocotrienol and its synthetic derivatives in HER-2/neu overexpressing breast adenocarcinoma cells. Biofactors  2013; 39(4): 485-93.
[http://dx.doi.org/10.1002/biof.1089] [PMID:  23361894] 
[66] 
Roberts DJ, Tan-Sah VP, Ding EY, et al. Hexokinase-II positively regulates glucose starvation-induced autophagy through TORC1 inhibition. Mol Cell  2014; 53(4): 521-33.
[http://dx.doi.org/10.1016/j.molcel.2013.12.019] [PMID:  24462113] 
[67] 
Chen Z, Zhang H, Lu W, et al. Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta  2009; 1787(5): 553-60.
[http://dx.doi.org/10.1016/j.bbabio.2009.03.003] [PMID:  19285479] 
[68] 
Jiang Q, Pan Y, Cheng Y, et al. Lunasin suppresses the migration and invasion of breast cancer cells by inhibiting matrix metalloproteinase-2/-9 via the FAK/Akt/ERK and NF-κB signaling pathways. Oncol Rep  2016; 36(1): 253-62.
[http://dx.doi.org/10.3892/or.2016.4798] [PMID:  27175819] 
[69] 
Ci Y, Qiao J, Han M. Molecular mechanisms and metabolomics of natural polyphenols interfering with breast cancer metastasis. Molecules  2016; 21(12): 1634.
[http://dx.doi.org/10.3390/molecules21121634] [PMID:  27999314] 
[70] 
Pawar VK, Panchal SB, Singh Y, et al. Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response. J Control Release  2014; 196: 295-306.
[http://dx.doi.org/10.1016/j.jconrel.2014.10.010] [PMID:  25459427] 
[71] 
Ding Y, Peng Y, Deng L, et al. Gamma-tocotrienol reverses multidrug resistance of breast cancer cells with a mechanism distinct from that of atorvastatin. J Steroid Biochem Mol Biol  2017; 167: 67-77.
[http://dx.doi.org/10.1016/j.jsbmb.2016.11.009] [PMID:  27864002] 
[72] 
Fernandes RS, Silva JO, Seabra HA, et al. α- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models in vivo. Biomed Pharmacother  2018; 103: 1348-54.
[http://dx.doi.org/10.1016/j.biopha.2018.04.139] [PMID:  29864917] 
[73] 
Figueroa D, Asaduzzaman M, Young F. Effect of chemotherapeutics and tocopherols on MCF-7 breast adenocarcinoma and KGN ovarian carcinoma cell lines in vitro. BioMed Res Int 2019.20196146972
[http://dx.doi.org/10.1155/2019/6146972] [PMID:  30766885] 
[74] 
Wei CW, Yu YL, Chen YH, et al. Anticancer effects of methotrexate in combination with α-tocopherol and α-tocopherol succinate on triple-negative breast cancer. Oncol Rep  2019; 41(3): 2060-6.
[http://dx.doi.org/10.3892/or.2019.6958] [PMID:  30628707] 
[75] 
Tiwari RV, Parajuli P, Sylvester PW. γ-Tocotrienol-induced endoplasmic reticulum stress and autophagy act concurrently to promote breast cancer cell death. Biochem Cell Biol  2015; 93(4): 306-20.
[http://dx.doi.org/10.1139/bcb-2014-0123] [PMID:  25844964] 
[76] 
Gu W, Prasadam I, Yu M, et al. Gamma tocotrienol targets tyrosine phosphatase SHP2 in mammospheres resulting in cell death through RAS/ERK pathway. BMC Cancer  2015; 15(1): 609.
[http://dx.doi.org/10.1186/s12885-015-1614-1] [PMID:  26315028] 
[77] 
Khallouki F, de Medina P, Caze-Subra S, et al. Molecular and biochemical analysis of the estrogenic and proliferative properties of vitamin E compounds. Front Oncol  2016; 5: 287.
[http://dx.doi.org/10.3389/fonc.2015.00287] [PMID:  26779438] 
[78] 
Tam KW, Ho CT, Tu SH, et al. α-Tocopherol succinate enhances pterostilbene anti-tumor activity in human breast cancer cells in vivo and in vitro. Oncotarget  2017; 9(4): 4593-606.
[http://dx.doi.org/10.18632/oncotarget.23390] [PMID:  29435127] 

Rights & Permissions Print Cite

Article Metrics

4

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1573401316999200614164711	Print ISSN 1573-4013
Publisher Name Bentham Science Publisher	Online ISSN 2212-3881

Current Nutrition & Food Science

The Role of Vitamin E in Breast Cancer Treatment and Prevention: Current Perspectives

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Related Articles

Abstract